

>> Establishing Functional Acceptance Criteria for hiPSC-Neural MEA Seizure Liability Assays

Mike Clements^{1,✉}, Ksenia Blinova², Matthew Cato³, Khuram W Chaudhary⁴, Stacie Chvatal¹, Annie Delaunois⁵, Parker Ellingson¹, Tromondae K Feaster², Steve Fiene¹, Catherine Garrison⁴, Mohamed Kreir⁶, Norimasa Miyamoto^{7,8,9}, Katie Newman¹⁰, Bumpei Noda^{8,9}, Kimberly L Rockley¹⁰, Leandro Royer⁵, Timothy J Shafer¹¹, Christopher Strock¹², Ikuro Suzuki^{8,9}, Anke M Tukker¹³, Remco HS Westerink¹⁴, Takashi Yoshinaga⁷, Louisa AK Zolkiewski¹⁰

¹Axion BioSystems, Atlanta, GA, USA; ²Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA; ³GSK, Collegeville, PA, USA; ⁴Bristol-Myers Squibb, Lawrenceville, NJ, USA; ⁵UCB, Braine-l'Alleud, Belgium; ⁶J&J Innovative Medicine, Beerse, Belgium; ⁷Eisai Co., Ltd., Tsukuba, Ibaraki 300-2635, Japan; ⁸Tohoku Institute of Technology, Miyagi, 982-8577, Japan; ⁹VitroVo, Miyagi, 982-8577, Japan; ¹⁰Apconix Ltd, Macclesfield, SK10 4TG, UK; ¹¹Shafer Neurotox Consulting, LLC, Durham, NC, USA; ¹²Cyprotex, Watertown, MA, USA; ¹³Purdue University, IN, USA; ¹⁴Utrecht University, The Netherlands.

✉ Email: mclements@axionbio.com

